Expand ROIV Menu
ROIV MENU

ROIV Latest Press Releases

-- September 23, 2026 --

Roivant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Globe Newswire 7:00 AM
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus Globe Newswire 7:00 AM

-- September 8, 2026 --

Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study Globe Newswire 6:00 AM
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study Globe Newswire 6:00 AM

-- September 6, 2026 --

Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026 Globe Newswire 1:00 AM
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Globe Newswire 1:00 AM

-- August 27, 2026 --

Roivant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Globe Newswire 3:29 PM
Priovant Announces FDA Approval of LISRAYA (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S. Globe Newswire 3:28 PM

-- August 26, 2026 --

JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis Globe Newswire 11:11 AM

-- August 6, 2026 --

Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update Globe Newswire 7:00 AM
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026 Globe Newswire 7:00 AM
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS) Globe Newswire 7:00 AM

-- July 23, 2026 --

Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026 Globe Newswire 4:05 PM

-- May 20, 2026 --

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update Globe Newswire 7:00 AM

-- May 11, 2026 --

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 Globe Newswire 4:05 PM
Market Data Delayed 15 Minutes